Juxtaglomerular cell tumor
| Juxtaglomerular cell tumor | |
|---|---|
| Synonyms | Reninoma |
| Pronounce | N/A |
| Specialty | Nephrology, Oncology |
| Symptoms | Hypertension, hypokalemia, headache, dizziness |
| Complications | Hypertensive crisis, chronic kidney disease |
| Onset | Typically in young adults |
| Duration | Variable |
| Types | N/A |
| Causes | Neoplastic proliferation of juxtaglomerular cells |
| Risks | Unknown |
| Diagnosis | Imaging studies, biopsy, histopathology |
| Differential diagnosis | Renal artery stenosis, pheochromocytoma, primary hyperaldosteronism |
| Prevention | N/A |
| Treatment | Surgical resection |
| Medication | Antihypertensive drugs |
| Prognosis | Generally good with treatment |
| Frequency | Rare |
| Deaths | N/A |
Juxtaglomerular cell tumor (JGCT) is a rare neoplasm originating from the juxtaglomerular cells of the kidney. These cells are primarily involved in the regulation of blood pressure through the renin-angiotensin system. JGCT is most commonly diagnosed in young adults and is characterized by its potential to produce excessive amounts of renin, leading to secondary hypertension and hyperaldosteronism.
Etiology and Pathogenesis[edit]
The exact cause of JGCT remains unknown. However, it is believed to arise from the juxtaglomerular cells, which are specialized smooth muscle cells located in the walls of the afferent arterioles of the kidney. These cells play a crucial role in the regulation of blood pressure by secreting renin, a key enzyme in the renin-angiotensin-aldosterone system (RAAS).
Clinical Presentation[edit]
Patients with JGCT typically present with symptoms related to hypertension and hyperaldosteronism. These may include headache, fatigue, visual disturbances, and in severe cases, end-organ damage. Due to the tumor's excessive renin production, patients may also exhibit symptoms of hypokalemia such as muscle weakness and cramps.
Diagnosis[edit]
The diagnosis of JGCT involves a combination of clinical evaluation, laboratory tests, and imaging studies. Laboratory tests may reveal elevated plasma renin activity and aldosterone levels. Imaging studies, such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), are used to locate the tumor within the kidney.
Treatment[edit]
The primary treatment for JGCT is surgical removal of the tumor. Nephron-sparing surgery is preferred to preserve kidney function, especially in cases where the tumor is localized and the kidney's structure allows for partial resection. In some cases, antihypertensive medications may be required to manage blood pressure before and after surgery.
Prognosis[edit]
The prognosis for patients with JGCT is generally favorable following successful surgical removal of the tumor. Most patients experience a significant improvement in blood pressure and a decrease in renin and aldosterone levels postoperatively. Long-term follow-up is recommended to monitor for recurrence or the development of chronic kidney disease.
Epidemiology[edit]
JGCT is a rare entity, accounting for less than 1% of all kidney tumors. It has a slight predilection for females and is most commonly diagnosed in young adults, although cases have been reported across a wide age range.
NIH genetic and rare disease info[edit]
Juxtaglomerular cell tumor is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Juxtaglomerular cell tumor
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian